



**HAL**  
open science

## Insights from a new tool for meiotic induction in fission yeast.

Pei-Yun Jenny Wu

► **To cite this version:**

Pei-Yun Jenny Wu. Insights from a new tool for meiotic induction in fission yeast.. Cell Cycle, 2012, 11 (11), pp.2050. 10.4161/cc.20537 . inserm-00702711

**HAL Id: inserm-00702711**

**<https://inserm.hal.science/inserm-00702711>**

Submitted on 31 May 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

# Cell Cycle News & Views

## Cdk5-induced neuronal cell death: The activation of the conventional Rb-E2F G<sub>1</sub> pathway in post-mitotic neurons

Comment on: Futatsugu A, et al. *Cell Cycle* 2012; 11:1603–10; PMID:22456337; <http://dx.doi.org/10.4161/cc.20009>

Shin-ichi Hisanaga\* and Akiko Asada; Tokyo Metropolitan University; Hachioji, Japan; \*Email: [hisanaga-shinichi@tmu.ac.jp](mailto:hisanaga-shinichi@tmu.ac.jp); <http://dx.doi.org/10.4161/cc.20536>

Neurons can live for more than 80 years in the human brain; however, in some cases, they are also vulnerable and can die as a result of various factors. Since neurons cannot be replaced once they are lost, it is crucial to keep them healthy, and, therefore, to understand the mechanisms of their survival and death is important. Neurons are terminally differentiated cells, quiescent in their cell cycle activities. If mitotic activity is activated ectopically, neurons undergo cell death with incomplete DNA replication after reentering the cell cycle. Thus, cell cycle activation is a cause of neuronal cell death, which is associated with many neurodegenerative diseases, including Alzheimer.<sup>1</sup>

Cyclin-dependent kinases (Cdks) are key players in the promotion of cell cycle progression in proliferating cells. Cdk5 is the atypical member of the Cdk family, and it plays a role in many neuronal activities unrelated to the cell cycle.<sup>2</sup> Although Cdk5 displays kinase activity similar to cell cycle Cdks, it has a distinct subcellular localization. Unlike the localization of the cell cycle Cdks in the nucleus, the majority of Cdk5 activity is associated with membranes in the cytoplasm. Membrane binding is conferred by a myristoylated Cdk5 activator, p35. It is well documented that Cdk5 is deregulated by calpain-mediated cleavage of p35 to p25, a C-terminal Cdk5 activator fragment without the myristoylation site that translocates into the nucleus, leading to neuronal cell death. Membrane anchoring of active Cdk5 is a survival strategy for neurons.

The question of how Cdk5 causes neuronal cell death has been intensively investigated. One proposed hypothesis suggests that cell cycle is activated through Cdk5 phosphorylation of nuclear proteins. Neurons reentering

the cell cycle should accompany expression of cell cycle proteins. Considering expression of both Retinoblastoma (Rb) and E2Fs proteins in neurons, the Rb-E2Fs pathway is the most likely Cdk5 target. E2Fs are transcription factors controlling G<sub>1</sub> cell cycle progression, which is regulated by Rb. Hypophosphorylated Rb binds to and inhibits E2F activity, and when Rb is phosphorylated by Cdk4/6, it releases E2Fs to activate transcription activity. Although phosphorylation of Rb by Cdk5 is reported *in vitro*,<sup>3,4</sup> it was not known whether this cascade functions *in vivo*. Futatsugu et al. have shown that Cdk5 is a major kinase that phosphorylates Rb at sites phosphorylated by Cdk4/6 using Cdk5<sup>-/-</sup> mouse brains.<sup>5</sup> They also indicate that Cdk5-p25 stimulates E2F1 transcription activity, and although they detect the presence of Cdk5 activity and phosphorylated Rb in the nucleus of neurons, the levels are insufficient for E2F activation in normal mouse brains. They propose that the pathway is mobilized when deregulated Cdk5 activity is increased in the nucleus. This is the first report that describes upregulation of E2F1 transcription activity by Rb phosphorylation, the conventional G<sub>1</sub> progression mechanism in Cdk5-dependent neuron cell death.

There are also two other mechanisms involved in Cdk5 regulation of E2Fs that are worth noting. Kim et al. showed that Cdk5-p25 binds to and inhibits HDAC1 by phosphorylation, resulting in increased expression of cell cycle proteins including E2F1, which may further stimulate G<sub>1</sub> activity.<sup>6</sup> Zhang et al. reported that Cdk5-p35 binds E2F1 to inhibit dimer formation with DP1 in the nucleus of neurons in a kinase-independent manner.<sup>7</sup> When cell cycle activity is initiated, Cdk5 is exported from the nucleus, resulting in E2Fs that create the

transcriptionally active complex with DP1. It was recently reported that nuclear transport of Cdk5 is regulated by the p27 Cdk inhibitor<sup>8</sup> or Cdk5 activity itself.<sup>9</sup> Therefore, there are at least three different molecular mechanisms involved in aberrant neuronal activation of E2Fs, which may be used differently according to death paradigms of neurons. Further, it is known that E2F1 can upregulate expression of proteins involved in apoptosis, although it is likely that E2F activation upregulates expression of cell cycle proteins as described above. Considering the potential therapeutics for Cdk5-induced neurodegenerative diseases, it is important to determine which death-inducing signals activate which E2F activation pathways and which of cell cycle or apoptotic proteins the activated E2F upregulates.

### References

- Herrup K, et al. *Nat Rev Neurosci* 2007; 8:368-78; PMID:17453017; <http://dx.doi.org/10.1038/nrn2124>.
- Hisanaga S, et al. *J Neurochem* 2011; 115:1309-21; <http://dx.doi.org/10.1111/j.1471-4159.2010.07050.x>.
- Lee KY, et al. *J Biol Chem* 1997; 272:5622-6; PMID:9038171; <http://dx.doi.org/10.1074/jbc.272.9.5622>.
- Hamdane M, et al. *J Cell Sci* 2005; 118:1291-8; PMID:15741232; <http://dx.doi.org/10.1242/jcs.01724>.
- Futatsugu A, et al. *Cell Cycle* 2012; 11:1603-10; PMID:22456337; <http://dx.doi.org/10.4161/cc.20009>.
- Kim D, et al. *Neuron* 2008; 60:803-17; PMID:19081376; <http://dx.doi.org/10.1016/j.neuron.2008.10.015>.
- Zhang J, et al. *J Neurosci* 2010; 30:5219-28; PMID:20392944; <http://dx.doi.org/10.1523/JNEUROSCI.5628-09.2010>.
- Zhang J, et al. *J Biol Chem* 2010; 285:14052-61; PMID:20189989; <http://dx.doi.org/10.1074/jbc.M109.068262>.
- Asada A, et al. *J Cell Sci* 2012; In Press; PMID:22467861; <http://dx.doi.org/10.1242/jcs.100503>; <http://dx.doi.org/10.1242/jcs.100503>.


## Insights from a new tool for meiotic induction in fission yeast

Comment on: Guerra-Moreno A, et al. *Cell Cycle* 2012; 11:1620–4; PMID:22456336; <http://dx.doi.org/10.4161/cc.20051>

Pei-Yun Jenny Wu; Institute of Genetics and Development of Rennes; CNRS UMR 6290; Rennes, France;  
\*Email: [pei-yun.wu@univ-rennes1.fr](mailto:pei-yun.wu@univ-rennes1.fr); <http://dx.doi.org/10.4161/cc.200537>

Meiosis is the differentiation pathway by which diploid cells produce haploid progeny for sexual reproduction. This specialized process involves one round of DNA replication, exchange of genetic material through recombination and haploidization achieved by two consecutive nuclear divisions without an intervening S phase. Meiosis is a tightly regulated process, and the major steps in meiotic progression, including the duplication, recombination and segregation of the genome, are conserved among eukaryotes. The molecular mechanisms underlying these events have been the subject of extensive and fruitful investigations, in particular in two model systems, the budding yeast *Saccharomyces cerevisiae* and the fission yeast *Schizosaccharomyces pombe*. In a previous issue of *Cell Cycle*, Guerra-Moreno and colleagues presented a novel method for the synchronous induction of meiosis in fission yeast and used this approach to uncover new aspects of the meiosis-specific transcriptional program.

In fission yeast, meiosis involves a physiological transition from vegetative growth, and initiation of the process requires inputs from a number of pathways, such as nutrient sensing and response to stress. Upon nitrogen deprivation, haploid yeast cells mate to form diploids, which then undergo meiosis and produce four haploid spores (Fig. 1). A highly synchronous meiosis can be induced in *S. pombe* using a temperature-sensitive allele of the Pat1 kinase (*pat1-114*),<sup>1</sup> a key negative regulator of the meiotic cycle. This system has been a powerful research tool, allowing for important discoveries in meiosis-specific RNA splicing, gene expression, recombination and chromosome segregation. However, one of its major drawbacks is the requirement for a temperature shift, which has been shown to cause stress responses and changes in cellular physiology, notably in gene expression.<sup>2</sup> Moreover, this precludes further dissection of the process through combination with the many temperature-sensitive mutations that have been isolated in fission yeast, a significant resource for this model organism. To circumvent these issues, Guerra-Moreno et al. have developed a more optimal method



**Figure 1.** Meiosis in fission yeast results in the production of four haploid spores from a diploid cell. The Pat1 kinase is a negative regulator of the meiotic process and its inactivation allows for meiotic entry. Box: DNA contents of nuclei are indicated by 1C (haploid), 2C (diploid) and 4C (diploid after DNA replication/pre-meiotic S phase).

for the synchronous induction of meiosis in *S. pombe*.<sup>3</sup> Taking a chemical genetic strategy that has been used to regulate the activity of various families of kinases,<sup>4</sup> they have engineered a mutation of Pat1 that renders it sensitive to specific inhibition by an ATP analog. Inactivation of the kinase activity of this allele, *pat1.L95G*, after nitrogen deprivation resulted in synchronous entry into pre-meiotic S phase, progression through both meiotic divisions and formation of four haploid spores. The authors further validated this system by confirming the execution of characteristic splicing events that occur during meiosis.

In addition to establishing a promising new tool for the investigation of the mechanisms of meiotic progression, this work has already yielded interesting results regarding its regulation. First, the authors investigated

the transcriptional program of meiosis in fission yeast, in which hundreds of genes are expressed in successive waves.<sup>5</sup> They verified that this pattern is generally preserved in their new system, with one surprising exception: although a number of transcripts associated with stress response were previously shown to be activated upon meiotic induction, Guerra-Moreno and colleagues found a striking difference in the transcriptional profiles of these genes using the *pat1.L95G* allele, demonstrating that they are, in fact, only activated at later stages in the process. This indicates that the initial characterization of their expression pattern was significantly affected by the temperature shift used in previous experiments and suggests that it will be critical to re-evaluate particular aspects of the meiotic program of transcription. Second, the authors observed a delay in the timing of S phase entry in *pat1.L95G* compared with *pat1-114*, hinting at potential new roles for Pat1 independent of its kinase activity and identifying new directions for future research.

The results obtained using this induction system demonstrate its potential to contribute to our understanding of meiosis. The value and utility of such a method is further underscored by a second paper in this issue from Cipak et al., who have generated a different analog-sensitive allele of *pat1* that also achieves a highly synchronous meiosis.<sup>6</sup> These complementary studies provide new insights into meiotic progression and highlight the power of this approach.

### References

1. Iino Y, et al. *Proc Natl Acad Sci USA* 1985; 82:2447-51; PMID:16593556; <http://dx.doi.org/10.1073/pnas.82.8.2447>.
2. Chen D, et al. *Mol Biol Cell* 2003; 14:214-29; PMID:12529438; <http://dx.doi.org/10.1091/mbc.E02-08-0499>.
3. Guerra-Moreno A, et al. *Cell Cycle* 2012; 11:1620-4; <http://dx.doi.org/10.4161/cc.20051>.
4. Bishop AC, et al. *Trends Cell Biol* 2001; 11:167-72; PMID:11306297; [http://dx.doi.org/10.1016/S0962-8924\(01\)01928-6](http://dx.doi.org/10.1016/S0962-8924(01)01928-6).
5. Mata J, et al. *Nat Genet* 2002; 32:143-7; PMID:12161753; <http://dx.doi.org/10.1038/ng951>.
6. Cipak L, et al. *Cell Cycle* 2012; 11:1625-32; <http://dx.doi.org/10.4161/cc.20052>.

# DAPk silencing by DNA methylation conveys resistance to anti EGFR drugs in lung cancer cells

Comment on: Ogawa T, et al. *Cell Cycle* 2012; 11:1656–63; PMID:22157090; <http://dx.doi.org/10.4161/cc.20120>

Avital Eisenberg-Lerner and Adi Kimchi\*; Weizmann Institute of Science; Rehovot, Israel; \*Email: [adi.kimchi@weizmann.ac.il](mailto:adi.kimchi@weizmann.ac.il); <http://dx.doi.org/10.4161/cc.20538>

Epigenetic changes have key roles in the initiation and progression of tumors. A predominant epigenetic modification in cancer is the silencing of tumor-suppressor genes by promoter DNA methylation at CpG islands. Silencing of this group of genes, which suppress cell proliferation, inhibit metastases or promote cell death processes provides a strong positive selection to the tumor cells. Interestingly, such epigenetic alterations occur not only at the different stages of tumor development, but also contribute to the acquisition of drug resistance, a major difficulty in cancer treatment.<sup>1</sup> In a recent issue of *Cell Cycle*, Sidransky and colleagues describe an interesting example of specific gene silencing during the acquisition of drug resistance in malignant cells.<sup>2</sup> The authors analyzed the gene promoter methylation profiles of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) cell lines in comparison to their derivatives resistant to two anti-EGFR drugs, erlotinib (Tarceva) or cetuximab. The top ranked gene that was differentially methylated in resistant but not parental cells was identified as the tumor suppressor DAPk.<sup>2</sup>

DAPk is a calcium/calmodulin-regulated Ser/Thr protein kinase that is implicated in various apoptotic, necrotic and autophagic cell death scenarios.<sup>3,4</sup> Hypermethylation of the DAPk promoter has been documented in a large spectrum of human malignancies.<sup>4</sup> The study by Ogawa et al. now describes DAPk as an essential factor for the successful treatment of NSCLC cell lines with anti-EGFR drugs and demonstrates the correlation between specific methylation of the DAPk promoter and acquisition of drug-resistance.<sup>2</sup> DAPk protein expression was, accordingly, low in the drug resistant cells. Remarkably, re-introduction of DAPk into the resistant cells by stable transfection restored the sensitivity of NSCLC cells to both erlotinib and cetuximab. Moreover,

knockdown of DAPk protein expression in the parental, drug-sensitive, cells induced resistance to both drugs. This highlights the significance of DAPk in mediating cell death processes that are initiated by the anti-EGFR treatment, and that loss of DAPk leads to drug resistance and thus provides to these cells a significant growth advantage. Conversely, in the HNSCC cells, the resistance appeared to be DAPk-independent. This is most likely due to the fact that the DAPk promoter was already methylated to some extent in the parental HNSCC cells prior to attaining resistance. Thus, the specific genetic makeup of different malignant cell populations at different stages has a dramatic influence on the success of different therapeutic interventions.

The multiple functions of DAPk in sensitizing cells to apoptotic and necrotic responses, in mediating autophagy and in blocking metastasis contribute to its tumor-suppressive properties. It is therefore not surprising that a modification that eliminates expression of this gene will be positively selected during tumorigenesis. The data presented by Ogawa et al. suggest that from the various stochastic epigenetic changes that occurred through the course of the drug treatment, cells that acquired silencing of the DAPk gene survived and created a subpopulation of resistant cells that prevailed. One of the future challenges will be to discover the molecular mechanisms that link DAPk to the cytotoxicity induced by the anti-EGFR drug. Interestingly, EGFR inhibitors have been recently documented to elevate reactive oxygen species in cells and to induce cytotoxicity through oxidative stress.<sup>5</sup> We have previously reported that DAPk is a major regulator of the cellular response to oxidative stress, acting through activation of protein kinase D and JNK to mediate both programmed necrosis as well as autophagy.<sup>6,7</sup> It is therefore plausible that the resistance to cytotoxicity of the anti-EGFR agents demonstrated

here is due to loss of this important redox-sensitive, death-promoting mechanism, which is mediated by DAPk. Previous reports also connected the loss of DAPk expression with resistance to other chemotherapeutic agents used to treat gastric cancer.<sup>8</sup> Like the anti-EGFR therapy, a significant part of chemotherapy-induced cytotoxicity is via induction of oxidative stress<sup>9</sup> and may, therefore, be dependent on DAPk. Finally, it should be stressed that further studies are required to clinically confirm the cell culture findings reported in this work by measuring the methylation status of DAPk in tumor specimens obtained from patients who acquired drug resistance along the course of treatment. The clinical data will indicate whether the assessment of DAPk methylation may be an important factor in choosing a specific course of therapy and predicting drug resistance.

## References

1. Yoo CB, et al. *Nat Rev Drug Discov* 2006; 5:37-50; PMID:16485345; <http://dx.doi.org/10.1038/nrd1930>.
2. Ogawa T, et al. *Cell Cycle* 2012; 11: In Press; PMID:22157090; <http://dx.doi.org/10.4161/cc.20120>.
3. Bialik S, et al. *Annu Rev Biochem* 2006; 75:189-210; PMID:16756490; <http://dx.doi.org/10.1146/annurev.biochem.75.103004.142615>.
4. Bialik S, et al. *Semin Cancer Biol* 2004; 14:283-94; PMID:15219621; <http://dx.doi.org/10.1016/j.semcancer.2004.04.008>.
5. Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, Sobhakumari A, et al. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. *Cancer Res* 2011; 71:3932-40; PMID:21482679; <http://dx.doi.org/10.1158/0008-5472.CAN-10-3425>.
6. Eisenberg-Lerner A, et al. *Cell Death Differ* 2007; 14:1908-15; PMID:17703233; <http://dx.doi.org/10.1038/sj.cdd.4402212>.
7. Eisenberg-Lerner A, et al. *Cell Death Differ* 2012; 19:788-97; PMID:22095288; <http://dx.doi.org/10.1038/cdd.2011.149>.
8. Zhang X, et al. *Anticancer Res* 2010; 30:915-21; PMID:20393015.
9. Wondrak GT. *Antioxid Redox Signal* 2009; 11:3013-69; PMID:19496700; <http://dx.doi.org/10.1089/ars.2009.2541>.

# Cancer cell death and selection: Unexpected putative roles for pRb2/p130, BORIS and CTCF in endoplasmic stress response maintained by the T-antigen

Comment on: Macaluso M, et al. *Cell Cycle* 2012; 11:1841–50; PMID:22544282; <http://dx.doi.org/10.4161/cc.20242>

Christian Bronner\* and Ali Hamiche; Institut de Génétique et de Biologie Moléculaire et Cellulaire; Centre National de la Recherche Scientifique; UMR7104; INSERM U964; Université de Strasbourg; Strasbourg, France; \*Email: [bronnerc@igbmc.fr](mailto:bronnerc@igbmc.fr); <http://dx.doi.org/10.4161/cc.20659>

Endoplasmic reticulum (ER) stress can affect the function of both oncogenes and tumor suppressor genes, conducting to altered signaling pathways regulating cell proliferation and homeostasis.<sup>1</sup> However, the mechanisms by which ER stress affects the function of oncogenes and tumor suppressor genes remain elusive. In a recent issue of *Cell Cycle*, Macaluso et al.<sup>2</sup> investigated the contribution of the chromatin insulator CCCTC-binding factor (CTCF) and of brother of the regulator of the imprinted site (BORIS) to the role of the large T antigen (T-Ag) in maintaining chronic ER stress. T-Ag is known to inactivate both p53 and pRB family proteins (pRB1/p105, pRB2/p130 and p107).<sup>3</sup> As such, the authors hypothesized that BORIS, CTCF and pRB2/p130 may have altered behaviors in order to maintain chronic ER stress in T-Ag-positive cancer cells.


CTCF can be considered as a potential tumor-suppressor factor, whereas BORIS (CTCF-L) has to be considered as a new oncogene.<sup>4</sup> Current literature suggests that CTCF and BORIS, both exhibiting an 11 zinc finger have DNA binding competition activities and thus elicit opposite changes in gene expression. CTCF is an evolutionarily conserved and ubiquitously expressed protein that binds to approximately 20,000 sites in the human genome.<sup>4</sup> Ectopic expression of CTCF in various normal and tumoral human cell lines inhibits cell division and clonogenicity. BORIS gene expression is predominantly epigenetically controlled by DNA methylation, considering that its activation requires the demethylation of its promoter, a mechanism frequently occurring in cancers due to global genome-wide hypomethylation.<sup>5</sup>

In the paper by Macaluso et al.,<sup>2</sup> the authors tried to demonstrate that the T-Ag, conferring oncogenic properties to the Polyomavirus, may contribute to maintain altered signaling pathways triggered by Rb2/p130, BORIS and CTCF. This study performed on medulloblastoma cells, nicely brings further insights

to their previous work, in which they could show that CTCF and BORIS directly bind the Rb2/p130 promoter and thus have a transcriptional regulatory effect on this gene.<sup>6</sup> Presently, they could demonstrate that CTCF binds to the pRB2/p130 promoter only in T-Ag-negative cells, suggesting that the presence of the T-Ag alters the binding of CTCF.<sup>2</sup> However, it is not yet known whether, this modification selectively occurs for the pRB2/p130 promoter or only for some promoters, or whether it is a whole genome-wide modification, which would be interesting to investigate. Furthermore, they found that pRB2/p130 interacts with either CTCF or with BORIS, since they could determine that pRB2/p130 co-immunoprecipitates and co-localizes with these proteins (Fig. 1). Surprisingly, it was observed that these complexes exclusively occur in the ER of medulloblastoma tissues in

contrast to medulloblastoma cell lines, where they occur in the nucleus as well in the cytoplasm. ER stress can be induced by hypoxia or low glucose levels. Macaluso et al. observed,<sup>2</sup> in T-Ag-negative cells, that glucose deprivation induced perinuclear aggregates of pRB2/p130 with BORIS and CTCF an event that is already occurring in T-Ag-positive cells under normal glucose conditions (Fig. 1). Additionally, ER stress seems to discard the pro-active form at the expense of the active form of caspase 12 (Fig. 1).<sup>2</sup>

The most encouraging observation made by Macaluso et al.,<sup>2</sup> is that T-Ag appears to prepare cancer cells for continued cell death dictated by a microenvironment poor in nutrients, i.e., low glucose levels, via inducing perinuclear aggregates of pRB2/p130 with CTCF and BORIS. The significance of the accumulation of these perinuclear aggregates is unclear,



**Figure 1.** Sub-cellular localization of pRb2/p130, CTCF, BORIS in T-Ag positive cells (BsB7) and T-Ag negative cells (Bs1a) in normal conditions and ER stress conditions (glucose deprivation). Separate icons of the proteins means diffuse localization whereas pooled icons mean aggregated proteins located at perinuclear sites. ER; endoplasmic reticulum. Nu; nucleus.

i.e., whether it is due to redistribution or it comes from an increase in the protein synthesis, the latter being a more plausible hypothesis. Indeed, the ER is the major site for folding and trafficking. When the ER is stressed by unfolded proteins, it elicits a classic adaptive response known as unfolded protein response (UPR).<sup>7</sup> Aggresome-like induced structures (ALIS) are known to result from transient aggregation of ubiquitinated proteins in ER stress response.<sup>8</sup> A crosstalk between UPR and

ALIS was recently reported.<sup>8</sup> Obtaining information as to whether pRb2/p130, BORIS and CTCF are affected by unfolding, ubiquitination or truncation will probably shed light on how the subcellular localization of CTCF, BORIS and pRb2/p130 is tuned to orchestrate interconnected p53-independent signaling pathways leading to cancer cell death in Polyomavirus-infected cells. Furthermore, it will unravel how cancer cells can be selected for survival and thus acquire resistance to cell death signaling.

#### References

1. Gorman AM, et al. *Pharmacol Ther* 2012; 134:306-16; PMID:22387231; <http://dx.doi.org/10.1016/j.pharmthera.2012.02.003>.
2. Macaluso M, et al. *Cell Cycle* 2012; 11: In press; PMID:22544282; <http://dx.doi.org/10.4161/cc.20242>.
3. Caracciolo V, et al. *J Cell Biochem* 2010; 110:182-90; PMID:20336668.
4. Millau JF, et al. *Biochem Cell Biol* 2011; 89:505-13; PMID:21970734; <http://dx.doi.org/10.1139/o11-052>.
5. de Necochea-Campion R, et al. *J Transl Med* 2011; 9:213; PMID:22168535; <http://dx.doi.org/10.1186/1479-5876-9-213>.
6. Fiorentino FP, et al. *Mol Cancer Res* 2011; 9:225-33; PMID:21325284; <http://dx.doi.org/10.1158/1541-7786.MCR-10-0493>.
7. Ron D, et al. *Nat Rev Mol Cell Biol* 2007; 8:519-29; PMID:17565364; <http://dx.doi.org/10.1038/nrm2199>.
8. Liu XD, et al. *J Biol Chem* 2012; In press; PMID:22518844.

## A killer promoting survival: p53 as a selective means to avoid side effects of chemotherapy

Comment on: van Leeuwen IMM, et al. *Cell Cycle* 2012; 11:1851–61; PMID:22517433; <http://dx.doi.org/10.4161/cc.20254>


Dominique Kranz<sup>1</sup> and Matthias Dobbstein<sup>2</sup>; <sup>1</sup>German Cancer Research Center; Heidelberg, Germany; <sup>2</sup>Göttingen Center of Molecular Biosciences; University of Göttingen; Göttingen, Germany; Email: [d.kranz@dkfz-heidelberg.de](mailto:d.kranz@dkfz-heidelberg.de) and [mdobbelt@gwdg.de](mailto:mdobbelt@gwdg.de); <http://dx.doi.org/10.4161/cc.20698>

Ideally, targeted cancer therapy is directed against tumor cells while sparing normal cells. But in reality, most of the chemotherapeutic drugs currently used in the clinics only partially confer this selectivity. As a result, all rapidly dividing tissues are affected by chemotherapy, resulting in severe side effects, such as immunosuppression, bleeding, diarrhea and hair loss.

Being the product of the most frequently mutated gene in cancer, the tumor suppressor p53 represents a highly attractive target for therapeutic approaches aiming at the selective killing of tumor cells. Some strategies for p53-based therapy rely on the reconstitution of wild-type p53 in tumor cells, e.g., by adenoviral gene delivery. More recently, the concept of converting mutant p53 into a killer of tumor cells was proposed.<sup>1</sup> Pharmacological reactivation of mutant p53 reportedly results in conformational changes, restoring DNA binding ability and transcriptional activity and, thus, the capability to induce cell cycle arrest, senescence or apoptosis.<sup>2</sup> However, the use of these drugs is still a challenge due to the heterogeneity of p53 mutations in tumors, each differing structurally and functionally.

In the past decade, cyclotherapy has emerged as a novel strategy where an initial treatment induces reversible growth arrest in normal cells, shielding them from classical chemotherapeutic treatment that only affects “cycling” cancer cells.<sup>3,4</sup>

p53-based cyclotherapy depends on the activation of wild-type p53 in normal cells. This concept seems counterintuitive at first glance, since p53 is mostly known as an inducer of cell death—obviously an undesirable effect with regard to normal cells of patients. However, moderately activating p53 rather results in cell cycle arrest than apoptosis. The induction of p53 may also protect cells by induction of repair genes or by altering the proapoptotic DNA damage response.<sup>5</sup> In this context, p53 serves as a discriminator between normal cells, with wild-type p53 and tumor cells lacking functional p53. Patients with tumors bearing p53 mutations could benefit from this combinatorial approach: Initial treatment with a p53 activator spares healthy tissue from cytotoxic effects associated with classical chemotherapy, and only tumor cells harboring p53 mutations are eliminated.



**Figure 1.** p53-mediated chemoprotection. Some chemotherapeutics are largely restricted in their efficacy to specific phases in the cell cycle. Nucleoside analogs (gemcitabine, cytarabine) work in S-phase, whereas taxanes and vinca alkaloids act on mitotic cells. Moderate activation of p53 arrests cells in G1 or G2, protecting p53-proficient cells (but not p53 mutant tumor cells) against these drugs.

Previous studies indicate that pretreatment with the p53 activator nutlin-3 protected human fibroblasts from taxanes<sup>6</sup> and human immortalized keratinocytes from nucleoside analogs<sup>7</sup> as well as from cell death induced by UV irradiation.<sup>5</sup>

In a previous issue of *Cell Cycle*, Leeuwen and colleagues extended this approach, showing that a variety of p53-activating strategies (actinomycin D, nutlin-3, tenovin-6, leptomycin B) led to reversible cell cycle arrest in human fibroblasts, protecting them from drugs that are active in S phase (gemcitabine and cytarabine) and M phase (vinblastine, vinorelbine).<sup>8</sup> Thus, arresting normal cells may provide a promising strategy of chemoprotection, enabling the use of higher doses of chemotherapeutics in patients.

However, fibroblasts are not the cells harmed by the side effects of chemotherapy in first place. Chemotherapy mostly damages highly proliferating tissues like bone marrow, epithelia of the digestive tract and hair follicles. Further investigations are required to evaluate if cells from these tissues are protected by p53-mediated cyclotherapy.

The study by Leeuwen et al. also indicates that sometimes p53-mutant and p53-null cell lines were protected by cyclotherapy, depending on the drug used for pre-treatment, potentially compromising the therapeutic efficacy.<sup>8</sup> In contrast, this effect was not observed for the p53-selective drug, nutlin-3.

As nutlin-3 interacts with MDM2, a negative regulator of p53, its effects are highly p53-dependent.<sup>9</sup> The major disadvantage of nutlin-3 is that it has not been clinically approved so far. For instance, p53-induced myelodepression may limit its use. Phase I clinical trials are currently ongoing using the related compound RG7112 as a monotherapy for the treatment of hematologic neoplasms (NCT00623870) and solid tumors (NCT00559533).

Critical issues remain to be addressed: Is p53-based cyclotherapy clinically applicable? Are there dose-limiting effects of combinatorial treatments? What impact has p53 preactivation on the side effects of chemotherapy in non-proliferating cells, e.g. neurons or cardiomyocytes?

Beyond understanding the underlying mechanisms of p53 as a chemoprotector, the

feasibility of the combinatorial treatment needs to be verified in preclinical studies and clinical trials. This would finally exploit the most frequent genetic alteration in cancer for a selective therapy.

#### References

1. Bykov VJ, et al. *Nat Med* 2002; 8:282-8; PMID:11875500; <http://dx.doi.org/10.1038/nm0302-282>.
2. Wiman KG. *Oncogene* 2010; 29:4245-52; PMID:20498645; <http://dx.doi.org/10.1038/onc.2010.188>.
3. Blagosklonny MV, et al. *Cancer Res* 2001; 61:4301-5; PMID:11389048.
4. Blagosklonny MV, et al. *Cell Cycle* 2002; 1:375-82; PMID:12548008; <http://dx.doi.org/10.4161/cc.1.6.259>.
5. Kranz D, et al. *J Cell Biol* 2008; 182:197-213; PMID:18625847; <http://dx.doi.org/10.1083/jcb.200712014>.
6. Carvajal D, et al. *Cancer Res* 2005; 65:1918-24; PMID:15753391; <http://dx.doi.org/10.1158/0008-5472.CAN-04-3576>.
7. Kranz D, et al. *Cancer Res* 2006; 66:10274-80; PMID:17079445; <http://dx.doi.org/10.1158/0008-5472.CAN-06-1527>.
8. van Leeuwen IMM, et al. *Cell Cycle* 2012; 11:1851-61; <http://dx.doi.org/10.4161/cc.20254>.
9. Vassilev LT, et al. *Science* 2004; 303:844-8; PMID:14704432; <http://dx.doi.org/10.1126/science.1092472>.